New Sizes of Medtronic Resolute Integrity Target Long Coronary Lesions

New sizes of implantable medical device target long coronary lesions common among diabetes patients

 

February 25, 2013
Medtronic Resolute Integrity Stent FDA Approval 34, 38 mm

The 34 and 38 mm lengths of the Medtronic Resolute Integrity drug-eluting stent in diameters of 3, 3.5 and 4 mm with an indication for patients with diabetes are available to cardiac catheterization laboratories nationwide. These new sizes of the Resolute Integrity stent enable the treatment of long coronary lesions, which are generally considered to span more than 27 mm.

Like the core sizes, the 34 and 38 mm lengths of the Resolute Integrity stent are indicated for treating the coronary artery disease of patients with diabetes, who commonly present with long lesions.

The 34 and 38 mm lengths were FDA approved in February 2013.

For more information: www.medtronic.com